Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease

被引:122
|
作者
Martín-Aparicio, E
Yamamoto, A
Hernández, F
Hen, R
Avila, JS
Lucas, JJ [1 ]
机构
[1] Univ Autonoma Madrid, CSIC, Fac Ciencias, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain
[2] Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA
来源
JOURNAL OF NEUROSCIENCE | 2001年 / 21卷 / 22期
关键词
Huntington's disease; aggregates; conditional transgenic mouse model; fast reversal; proteasome; absence of cell death;
D O I
10.1523/JNEUROSCI.21-22-08772.2001
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Neuronal intranuclear inclusions are a histopathological hallmark of Huntington's disease. Nevertheless, the precise mechanism by which they are formed and their relevance to neuronal cell death and/or dysfunction remains unclear. We recently generated a conditional mouse model of Huntington's disease (HD94) in which silencing expression of mutated huntingtin led to the disappearance of intranuclear aggregates and amelioration of the behavioral phenotype. Here, we analyze primary striatal neuronal cultures from HD94 mice to explore the dynamics of aggregate formation and reversal, the possible mechanisms involved, and the correlation between aggregates and neuronal death. In parallel, we examine symptomatic adult HD94 mice in similar studies and explored the relationship between aggregate clearance and behavioral reversal. We report that, in culture, aggregate formation and reversal were rapid processes, such that 2 d of transgene expression led to aggregate formation, and 5 d of transgene suppression led to aggregate disappearance. In mice, full reversal of aggregates and intranuclear mutant huntingtin was more rapid than reported previously and preceded the motor recovery by several weeks. Furthermore, the proteasome inhibitor lactacystin inhibited the aggregate clearance observed in culture, thus indicating that aggregate formation is a balance between the rate of huntingtin synthesis and its degradation by the proteasome. Finally, neither expression of the mutant huntingtin nor aggregates compromised the viability of HD94 cultures. This correlated with the lack of cell death in symptomatic HD94 mice, thus demonstrating that neuronal dysfunction, and not cell loss, triggered by mutant huntingtin underlies symptomatology.
引用
收藏
页码:8772 / 8781
页数:10
相关论文
共 50 条
  • [21] The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model
    van Hagen, Martijn
    Piebes, Diewertje G. E.
    de Leeuw, Wim C.
    Vuist, Ilona M.
    van Roon-Mom, Willeke M. C.
    Moerland, Perry D.
    Verschure, Pernette J.
    BMC GENOMICS, 2017, 18
  • [22] The dynamics of early-state transcriptional changes and aggregate formation in a Huntington’s disease cell model
    Martijn van Hagen
    Diewertje G. E. Piebes
    Wim C. de Leeuw
    Ilona M. Vuist
    Willeke M. C. van Roon-Mom
    Perry D. Moerland
    Pernette J. Verschure
    BMC Genomics, 18
  • [23] ‘Tissue’ transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease
    P G Mastroberardino
    C Iannicola
    R Nardacci
    F Bernassola
    V De Laurenzi
    G Melino
    S Moreno
    F Pavone
    S Oliverio
    L Fesus
    M Piacentini
    Cell Death & Differentiation, 2002, 9 : 873 - 880
  • [24] 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease
    Mastroberardino, P
    Iannicola, C
    Nardacci, R
    Bernassola, F
    De Laurenzi, V
    Melino, G
    Moreno, S
    Pavone, F
    Oliverio, S
    Fesus, L
    Piacentini, M
    CELL DEATH AND DIFFERENTIATION, 2002, 9 (09): : 873 - 880
  • [25] Cardiac Conduction Disease in Huntington's Disease Mouse Model (BACHD)
    Zhu, Yujie
    Shamblin, Isaac
    Ali, Sameen
    Gray, Michelle
    Huke, Sabine
    FASEB JOURNAL, 2018, 32 (01):
  • [26] MYELOID CELL FUNCTION IN MOUSE MODELS OF HUNTINGTON'S DISEASE
    Andre, R.
    Schure, U.
    Magnusson, A.
    Lahiri, N.
    Smith, D.
    Lowdell, M. W.
    Bates, G.
    Bjorkqvist, M.
    Tabrizi, S. J.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2010, 81 : A5 - A6
  • [27] Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
    Chen, Xi
    Wu, Jun
    Lvovskaya, Svetlana
    Herndon, Emily
    Supnet, Charlene
    Bezprozvanny, Ilya
    MOLECULAR NEURODEGENERATION, 2011, 6
  • [28] Brain pericyte response in a mouse model of Huntington's disease
    Padel, T.
    Ozen, I.
    Roth, M.
    Paul, G.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2017, 37 : 479 - 479
  • [29] Progressive neuronal atrophy in a mouse model of Huntington's disease
    Raza, A. S.
    Davies, S. W.
    JOURNAL OF ANATOMY, 2007, 210 (05) : 607 - 607
  • [30] Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease
    Turmaine, M
    Raza, A
    Mahal, A
    Mangiarini, L
    Bates, GP
    Davies, SW
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (14) : 8093 - 8097